Related Experiment Video
Updated: Aug 6, 2025

Measuring Caspase Activity Using a Fluorometric Assay or Flow Cytometry
Published on: March 24, 2023
Executioner caspases restrict mitochondrial RNA-driven Type I IFN induction during chemotherapy-induced apoptosis
Shane T Killarney1, Rachel Washart1, Ryan S Soderquist1
1Department of Pharmacology and Cancer Biology, Duke University, Durham, NC, USA.
Abstract:
During apoptosis, mitochondrial outer membrane permeabilization (MOMP) enables certain mitochondrial matrix macromolecules to escape into the cytosol. However, the fate of mitochondrial RNA (mtRNA) during apoptosis is unknown. Here, we demonstrate that MOMP results in the cytoplasmic release of mtRNA and that executioner caspases-3 and -7 (casp3/7) prevent cytoplasmic mtRNA from triggering inflammatory signaling. In the setting of genetic or pharmacological casp3/7 inhibition, apoptotic insults result in mtRNA activation of the MDA5/MAVS/IRF3 pathway to drive Type I interferon (IFN) signaling. This pathway is sufficient to activate tumor-intrinsic Type I IFN signaling in immunologically cold cancer models that lack an intact cGAS/STING signaling pathway, promote CD8+ T-cell-dependent anti-tumor immunity, and overcome anti-PD1 refractoriness in vivo. Thus, a key function of casp3/7 is to inhibit inflammation caused by the cytoplasmic release of mtRNA, and pharmacological modulation of this pathway increases the immunogenicity of chemotherapy-induced apoptosis.
Insights
During apoptosis, mitochondrial RNA (mtRNA) is released into the cytoplasm. Executioner caspases-3 and -7 normally prevent this mtRNA from causing inflammation, but inhibiting them can boost anti-tumor immunity.
Area of Science:
- Cell Biology
- Immunology
- Cancer Research
Background:
- Mitochondrial outer membrane permeabilization (MOMP) during apoptosis releases macromolecules.
- The fate and role of mitochondrial RNA (mtRNA) during apoptosis remain unclear.
Purpose of the Study:
- To investigate the release and function of mtRNA during apoptosis.
- To determine the role of executioner caspases in regulating mtRNA-mediated signaling.
- To explore the therapeutic potential of modulating this pathway in cancer.
Main Methods:
- Investigated mtRNA release during MOMP.
- Utilized genetic and pharmacological inhibition of caspases-3 and -7 (casp3/7).
- Assessed activation of the MDA5/MAVS/IRF3 pathway and Type I interferon (IFN) signaling.
- Evaluated anti-tumor immunity in immunologically cold cancer models.
Main Results:
- MOMP leads to the cytoplasmic release of mtRNA.
- Casp3/7 inhibit inflammatory signaling triggered by cytoplasmic mtRNA.
- Inhibition of casp3/7 activates the MDA5/MAVS/IRF3 pathway, driving Type I IFN signaling.
- This pathway enhances CD8+ T-cell-dependent anti-tumor immunity and overcomes anti-PD1 resistance.
Conclusions:
- Caspases-3 and -7 play a crucial role in suppressing inflammation from released mtRNA.
- Modulating casp3/7 activity can enhance the immunogenicity of chemotherapy-induced apoptosis.
- Targeting this pathway offers a strategy to improve cancer immunotherapy outcomes.
Related Concept Videos
Caspases
The Intrinsic Apoptotic Pathway
The Extrinsic Apoptotic Pathway
Apoptosis
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Overview of Cell Death
Cell death was observed in the early 19th century, but there was no experimental evidence to prove it. In 1842, Carl Vogt first discovered cell death in a metamorphic toad; however, it was not termed ‘cell death.’ Scientists discovered different cell death pathways only in the...

